All articles

A New Word in Type 2 Diabetes Treatment and NAD+ Activation: Imeglimin

A New Word in Type 2 Diabetes Treatment and NAD+ Activation: Imeglimin

in pictures and a few words

What it is and why it matters

It is a tablet for type 2 diabetes. It was approved in Japan in 2021, and it is unlike the others: it acts on the cells’ “power stations”.

  • Sold only in Japan, by prescription; importing it by mail is a gray area
  • A relative of metformin, but its molecule is a ring, not a chain
  • It lowers blood sugar moderately; valued because it can be used when other drugs cannot

How it works

Inside cells there are mitochondria — “power stations”. The tablet acts on them, and this changes two things at once.

  • In response to food, the pancreas releases more insulin
  • Tissues respond better to insulin — this was seen in people in a small study
  • It does not slow cell breathing — so, unlike metformin, no route to acidic blood
TabletCells’ “power stations”More insulin for meals

Important. With severe illness, dehydration or together with metformin, the blood can still turn acidic: the tablet does not give full protection.

Link to longevity medicine

In the cells that make insulin, the tablet raises the supply of a molecule without which the “power stations” cannot get energy from food. This boosts insulin release.

  • It is the only approved diabetes drug that works this way
  • Its supply falls with age and in diabetes; it is much talked about in longevity medicine
  • Shown in experiments; no one has studied a rejuvenating effect in people

How much it lowers blood sugar

Moderately — about as much as sitagliptin and similar tablets. Metformin, injections like semaglutide and tablets that remove sugar in the urine lower it more.

  • The effect held for two years and did not weaken
  • In older people it worked no worse than in younger ones
  • There were no severe drops in blood sugar in the studies

Who it suits best

The tablet worked best in lean, older, non-smoking people whose pancreas releases little insulin.

  • Worth considering with kidney disease (works just as well) or poor metformin tolerance
  • The least benefit is expected in people with high body weight on high doses of insulin
  • In fatty liver disease, liver tests improved on it

If you have kidney disease

With kidney disease, many diabetes tablets are not allowed or stop working. This one was taken even in severe kidney disease and on dialysis — at a lower dose.

  • The kidneys remove the tablet: the worse they work, the lower the dose
  • With weak kidneys, usually 500 mg twice a day; with very weak ones, once a day
  • In observations, kidney function did not get worse on the tablet
Kidney function testDoctor picks the doseRepeat the test regularly

How to take it

The usual dose is 1000 mg twice a day. Food does not interfere: before or after meals is fine.

  • Not raised above 1000 mg twice a day: no extra benefit, only more side effects
  • The best partner is sitagliptin and similar tablets: together they complement each other
  • Judge the benefit no earlier than after 3 months: the effect builds up slowly
Tablet twice a dayWith or without foodResult — in 3 months

What you may feel

The main side effect is the gut: nausea and diarrhea. More often together with metformin and in people diagnosed with diabetes recently.

  • Most often in the first four months, usually mild
  • About half of these cases pass within a week
  • If your stomach bothers you, the doctor may lower the metformin dose
Nausea or diarrheaHalf pass within a weekBothers you — tell doctor

Important. Mild diarrhea in the first weeks is no reason to quit. With vomiting, severe diarrhea or dehydration — pause the tablet and contact your doctor right away.

Who should see a doctor first

The tablet is prescribed by a doctor, who picks the dose based on a kidney test. If it cannot be obtained, a substitute from available drugs is also chosen by the doctor — it repeats only part of the effect.

  • Severe liver disease — the tablet has not been studied in it
  • You drink alcohol — talk to your doctor: the tablet has not been studied together with it
  • During treatment, the kidneys, complete blood count and cholesterol are checked

Important. If you don’t have diabetes — repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL): see a doctor; with diabetes, targets are individual (per your doctor’s plan), and sugar below 3.0 mmol/L (54 mg/dL) always means seeing a doctor.

In one sentence

It is a new tablet for type 2 diabetes: it lowers blood sugar moderately, but it also suits people with kidney disease. Sold only in Japan; the dose and a substitute are chosen by the doctor.

Frequently asked questions

Imeglimin is a tablet for type 2 diabetes and the only member of the new “glimins” class. Chemically it is a relative of metformin (both are guanidine derivatives), but the imeglimin molecule is closed into a ring (a tetrahydrotriazine), whereas metformin is a linear chain. Because of this they act differently on the same target in the mitochondrion — Complex I: metformin inhibits it non-competitively and reduces the cell's oxygen consumption, imeglimin — competitively and does not reduce oxygen consumption. Hence the main differences: imeglimin has no lactic acidosis risk by mechanism, it enhances insulin release through NAD+, potentially protects β-cells, and can be used in severe kidney disease all the way to dialysis. Metformin, in turn, lowers HbA1c more (by 1–1.5% versus 0.6–0.9%), costs pennies, and is available everywhere.

NAD+ is a carrier molecule without which mitochondria cannot extract energy; its supply in cells falls with age and in diabetes. Imeglimin switches on the “salvage pathway” in the β-cell — it induces the enzyme NAMPT, which reassembles NAD+ from used molecules. Then NAD+ is converted by the enzyme CD38 into the signaling molecule cADPR, which opens the calcium channel RyR, and calcium triggers insulin release in response to glucose. It is the only approved glucose-lowering drug in which raising NAD+ is built into the mechanism of action — unlike NAD+ precursor supplements (NR, NMN), which are not drugs. Important: the effect on NAD+ has been shown in the β-cell and in experiments; no one has studied a “rejuvenating” effect on the body in humans.

Moderately. In monotherapy (TIMES 1, 24 weeks, n=213) HbA1c fell by 0.87% relative to placebo; added to other drugs (TIMES 2, 52 weeks, n=714) — by 0.56–0.92%; added to insulin (TIMES 3) — by 0.60%; added to a DPP-4i (FAMILIAR) — by 1.02% relative to placebo at week 24 with the effect maintained for 104 weeks. In a network meta-analysis of 71,000 participants, 1000 mg × 2 gives −0.67% versus placebo and does not differ from the approved DPP-4is (sitagliptin and others); this is below injectable GLP-1s and SGLT2is. Imeglimin is chosen not for potency but for profile: safety in kidney disease, absence of lactic acidosis, a mechanism via the β-cell and NAD+. An important practical detail: the effect builds slowly — it reaches full strength after three months, and HbA1c partly “lags” because of prolonged erythrocyte lifespan (INFINITY), so the early effect is better assessed by glycated albumin.

By mechanism — no, and no cases were recorded in the registration program or observational cohorts. Lactic acidosis with metformin arises because it non-competitively inhibits Complex I, reduces the cell's oxygen consumption, and switches it to oxygen-free glycolysis, whose by-product is lactate. Imeglimin acts on the same Complex I but competitively: the maximum rate of the respiratory chain and oxygen consumption do not fall, and the glycolytic shift is not triggered. Caveats: this is a mechanistic and observational level of evidence; no dedicated studies have been done in people at high risk of acidosis (for example, alcohol abusers); in severe illness, dehydration, and in combination with metformin the usual vigilance remains.

Yes, and this is its main niche. The drug is excreted unchanged by the kidneys, so it accumulates as eGFR falls: in the phase 4 TWINKLE study (eGFR <45, 52 weeks), the pre-dose concentration at stage G4 (eGFR 15–29) was roughly twice that at G3b (1123–1370 versus 213.5–719.6 ng/mL) at the same 500 mg × 2/day dose; at stage G5, 500 mg × 1/day was used. On the basis of these data, in April 2025 the PMDA extended the label to eGFR <45. There is a small series (n=6) of 500 mg/day use in patients on hemodialysis and peritoneal dialysis with a significant reduction in fasting glucose. The author's practical conclusion: at G4 it is reasonable to reduce the dose further without waiting for side effects, rather than following the label mechanically.

On the key criterion — lactic acidosis — imeglimin is safer: alcohol increases lactate production and hinders its hepatic utilization, and the metformin label explicitly says to avoid excessive alcohol intake; imeglimin has no lactate-risk mechanism. On hypoglycemia, gastrointestinal tolerability, and cardiac effects the drugs are comparable; on the liver and kidneys imeglimin is rather preferable (not metabolized by the liver, data up to dialysis); on vitamin B12, metformin and alcohol produce a double deficiency, while imeglimin's effect has not been studied. But three caveats: no direct “imeglimin + alcohol” studies exist; alcohol by itself worsens diabetes control regardless of the pill; outside Japan imeglimin is unavailable. With moderate consumption both are acceptable with the usual caution; with abuse, metformin is contraindicated, and the real choice is other drug classes and treatment of the dependence.

Legally — only in Japan by prescription (処方箋医薬品); Japanese online clinics consult remotely and ship the drug by mail, but delivery is to Japanese addresses only. Under Japan's NHI insurance the therapy is inexpensive; retail without insurance costs 2–3 times more. Personal-import brokers are a gray zone: importing an unregistered drug formally violates the law (in Thailand — the Thai Drug Act B.E. 2510), the risk of customs seizure is about 30–50%, and authenticity is not guaranteed. Research-grade substance (MedChemExpress, Cayman, TargetMol) is a “not for human use” reagent without GMP, unsuitable for patients. Outside Japan the drug is approved nowhere; the probability of reaching the US/EU markets through the developer's own efforts is estimated at below 5%.

The mechanistically closest available combination is low-dose metformin XR (≤750 mg/day) + DPP-4i + an NAD precursor (nicotinamide riboside or NMN). Low-dose metformin acts on the same Complex I but is gentler on the stomach; a DPP-4i covers the incretin pathway — the very pairing that is additive with imeglimin on GLP-1; an NAD precursor is not a drug but a supplement with a weaker evidence base, but the pathway is the same. Such a “construction kit” confidently covers two of imeglimin's four pathways (Complex I and incretins), partially — NAD+, and does not cover the protection from ROS/mPTP. This is a compromise, not an equivalent. Selecting a specific regimen is the task of the treating physician, taking into account eGFR, tolerability, and comorbid conditions.

At the level of mechanism and experiments — yes; in humans on clinical outcomes — not yet proven. Imeglimin partially inhibits Complex I and corrects the Complex III deficit, reduces production of reactive oxygen species (ROS), and prevents opening of the mitochondrial permeability transition pore (mPTP) — an anti-apoptotic effect in the β-cell and endothelial cell that metformin lacks. Additionally, it improves endoplasmic reticulum structure and reduces ER stress, which increases glucose-stimulated insulin secretion. But to say “it protects in humans,” one needs a study in which patients' preservation of their own insulin secretion is measured over years — there is no such study. So the correct wording is “a claim to β-cell protection,” not a proven effect.

The portrait of the ideal candidate is made up of several features: a secretory phenotype of diabetes (the pancreas secretes little insulin — more common in East Asians, but found in anyone), a thin build, older age, non-smoking, chronic kidney disease G3b–G4 (eGFR 15–44), and intolerance of full-dose metformin — it was precisely such patients who responded best in the cluster and machine-learning analyses of the registration data and in FAMILIAR. An additional argument is fatty liver disease with elevated ALT: in observational studies imeglimin reduced ALT, AST, γ-GTP, and the FIB-4/FAST indices. The least likely responder is an obese insulin-resistant patient on large insulin doses. The combination of choice is a DPP-4i (104 weeks of FAMILIAR data); metformin in combination — keep at full dose if tolerated (reducing it costs about 0.5% HbA1c), and reduce to 500–750 mg/day if gastrointestinal symptoms interfere. The horizon for assessing the effect is a minimum of 12 weeks.

The dose is determined by eGFR, because the drug is excreted unchanged by the kidneys with active tubular secretion: at eGFR ≥45 mL/min/1.73 m² — 1000 mg × 2/day; at eGFR 15–44 — 500 mg × 2/day (population pharmacokinetic model, phase 1 in patients with impaired renal function, and phase 4 TWINKLE; PMDA label since April 2025); at eGFR <15, including dialysis — 500 mg × 1/day. Raising the dose above 1000 mg × 2 is pointless: absorption via OCT transporters saturates, and exposure grows more slowly than the dose while side effects grow faster. Food does not affect absorption — it can be taken before or after meals. The liver does not metabolize the drug; in moderate hepatic impairment exposure rises 1.5-fold without clinical significance; severe hepatic impairment has not been studied. No clinically significant interactions with metformin, sitagliptin, or transporter inhibitors (cimetidine) have been found.

The longest randomized data are from FAMILIAR: when added to a DPP-4i, the HbA1c reduction of 0.65% (−1.02% relative to placebo) at week 24 was maintained at week 104 (−0.55%) with no signs of waning and without hypoglycemia in patients over 65; a mixed-meal test showed a sustained improvement in insulin sensitivity. Real-world observations over 6–12 months confirm durability. In potency imeglimin equals the DPP-4is — in a network meta-analysis of 71,476 participants, 1000 mg × 2 does not differ statistically from sitagliptin, linagliptin, saxagliptin, and alogliptin — but the mechanism is different: DPP-4is prolong the life of incretins, whereas imeglimin increases their secretion (GLP-1 and GIP), directly amplifies insulin release through NAD+/cADPR, and improves tissue insulin sensitivity; so together they give more than each alone, and in the elderly on insulin the pairing allows some boluses to be removed (INSPIRE).

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question